To evaluate the effect of STING agonist treatment on alterations intumour immune profiles, we subjected the total RNA from tumours in the STINGagonist only and vehicle-treated mice to NanoString-based immune transcriptomicprofiling. This evidence concerns the gene STING1 and neoplasm.